BECONASE by GSK is clinical pharmacology mechanism of action following topical administration, beclomethasone dipropionate produces anti-inflammatory and vasoconstrictor effects. Approved for recurrence of nasal polyps following surgical removal. First approved in 1981.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
BECONASE is a metered-dose aerosol nasal spray containing beclomethasone dipropionate, a topical corticosteroid that reduces inflammation in the nasal passages. It is indicated for the recurrence of nasal polyps following surgical removal. The drug works as a pro-drug that is hydrolyzed to its active metabolite (B-17-MP), which has high topical anti-inflammatory activity through effects on multiple immune cell types and inflammatory mediators.
This legacy product is approaching loss of exclusivity with minimal spending data, signaling a small or maintenance-focused team structure.
CLINICAL PHARMACOLOGY Mechanism of Action Following topical administration, beclomethasone dipropionate produces anti-inflammatory and vasoconstrictor effects. The mechanisms responsible for the anti-inflammatory action of beclomethasone dipropionate are unknown. Corticosteroids have been shown to…
Worked on BECONASE at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on BECONASE offers limited career growth opportunities given the product's approaching loss of exclusivity and minimal active sponsorship. Roles are primarily focused on defending market share, managing pricing pressure, and transitioning to generic competition rather than driving innovation or expansion.